Back
Range Cancer Therapeutics ETF Stock Price Chart
The key to a $1.3T opportunity
This is a paid advertisement for Pacaso's Regulation A offering. Please read the offering circular and related risks at invest.pacaso.com.
Sell
34
CNCR
Range Cancer Therapeutics ETF
Last Price:
$8.86
Seasonality Move:
2.51%
7 Day Trial
ALL ACCESS PASS
$
7
FREE Copy of "2025 Gold Forecast: A Perfect Storm for Demand"
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report here-
The current trend is moderately bearish and CNCR is experiencing slight selling pressure.
Range Cancer Therapeutics ETF Price Chart Indicators
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 9.37 | Sell |
| 20-day SMA: | 9.47 | Sell |
| 50-day SMA: | 9.82 | Sell |
| 200-day SMA: | 12.89 | Sell |
| 8-day EMA: | 9.26 | Sell |
| 20-day EMA: | 9.15 | Buy |
| 50-day EMA: | 7.27 | Buy |
| 200-day EMA: | 2.92 | Buy |
Range Cancer Therapeutics ETF Technical Analysis Indicators
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.47 | Buy |
| Relative Strength Index (14 RSI): | 45.33 | Sell |
| Chaikin Money Flow: | -1105 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (8.68 - 9.86) | Sell |
| Bollinger Bands (100): | (9.65 - 12.51) | Sell |
Range Cancer Therapeutics ETF Technical Analysis
| Apr 29 | Apr 30 | May 1 | May 2 | May 5 | May 6 | May 7 | May 8 | May 9 | May 12 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr | May | |||||||||
| 29 | 30 | 01 | 02 | 05 | 06 | 07 | 08 | 09 | 12 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Technical Analysis for Range Cancer Therapeutics ETF Stock
Is Range Cancer Therapeutics ETF Stock a Buy?
-
Range Cancer Therapeutics ETF share price is 9.17 while CNCR 8-day simple moving average is 9.37, which is a Sell signal.
-
The stock price of CNCR is 9.17 while Range Cancer Therapeutics ETF 20-day SMA is 9.47, which makes it a Sell.
-
Range Cancer Therapeutics ETF 50-day simple moving average is 9.82 while CNCR share price is 9.17, making it a Sell technically.
-
CNCR stock price is 9.17 and Range Cancer Therapeutics ETF 200-day simple moving average is 12.89, creating a Sell signal.
CNCR Technical Analysis vs Fundamental Analysis
Sell
34
Range Cancer Therapeutics ETF (CNCR)
is a Sell
Is Range Cancer Therapeutics ETF a Buy or a Sell?
-
Range Cancer Therapeutics ETF stock is rated a SellThe current Range Cancer Therapeutics ETF [CNCR] share price is $9.17. The Score for CNCR is 34, which is 32% below its historic median score of 50, and infers higher risk than normal.
Range Cancer Therapeutics ETF Stock Info
Market Cap:
0
Price in USD:
9.17
Share Volume:
2.6K
Range Cancer Therapeutics ETF 52-Week Range
52-Week High:
16.27
52-Week Low:
7.88
Sell
34
Range Cancer Therapeutics ETF (CNCR)
is a Sell
Range Cancer Therapeutics ETF Share Price Forecast
-
What is the Range Cancer Therapeutics ETF stock price today?The Range Cancer Therapeutics ETF stock price is 9.17 USD today.
-
Will CNCR stock go up or go down?Range Cancer Therapeutics ETF> share price is forecast to RISE/FALL based on technical indicators
-
Is Range Cancer Therapeutics ETF overvalued?According to simple moving average, exponential moving average, oscillators, and other technical indicators, Range Cancer Therapeutics ETF is overvalued.
Is Range Cancer Therapeutics ETF Stock a Buy?
-
Range Cancer Therapeutics ETF share price is 9.17 while CNCR 8-day exponential moving average is 9.26, which is a Sell signal.
-
The stock price of CNCR is 9.17 while Range Cancer Therapeutics ETF 20-day EMA is 9.15, which makes it a Buy.
-
Range Cancer Therapeutics ETF 50-day exponential moving average is 7.27 while CNCR share price is 9.17, making it a Buy technically.
-
CNCR stock price is 9.17 and Range Cancer Therapeutics ETF 200-day simple moving average is 2.92, creating a Buy signal.
Technical Analysis of Range Cancer Therapeutics ETF
Should I short Range Cancer Therapeutics ETF stock?
-
CNCR Moving Average Covergence Divergence (MACD) indicator is 0.47, suggesting Range Cancer Therapeutics ETF is a Buy
-
Range Cancer Therapeutics ETF Relative Strength Index (RSI) is 45.33, which suggest Range Cancer Therapeutics ETF is oversold
-
The Bollinger Bands (25) for Range Cancer Therapeutics ETF is (8.68 - 9.86), which suggest Range Cancer Therapeutics ETF is a Sell
-
The Bollinger Bands (100) for Range Cancer Therapeutics ETF is (9.65 - 12.51), which suggest Range Cancer Therapeutics ETF is a Sell
* Range Cancer Therapeutics ETF stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.